logo

For the Inventor, By the Inventor

North Caldwell, NJ, United States of America

David L Pruess

This inventor holds 7 USPTO granted patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 1976-1980.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David L Pruess. Retrieved from https://idiyas.com/inventor/david-l-pruess

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 100.0

Average Co-Inventor Count = 2.6

ph-index = 3

Forward Citations = 23(Granted Patents)


Location History:

  • Passaic, NJ (US) (1976 - 1979)
  • North Caldwell, NJ (US) (1976 - 1980)

Company Filing History:

goldMedal7 out of 5,026 
 
Hoffmann-La Roche Inc.
 patents

Years Active: 1976-1980

Loading Chart...
7 patents (USPTO):Explore Patents
1. 4202819 - 2-(3-Alanyl)clavam antibiotic (1980-05-13),
2. 4152424 - Antibiotic 1745A/X and methods for the production thereof (1979-05-01),
3. 4070376 - Antibiotic 1745A/X and methods for the production thereof (1978-01-24),
4. 3993545 - Antibiotic X-1092 (1976-11-23),
5. 3992264 - Antibiotic 1745A/X and methods for the production thereof (1976-11-16),
6. 3956067 - Antibiotic X-372A (1976-05-11),
7. 3939139 - New antibiotic X-1092 (1976-02-17),

Title: David L. Pruess: Innovator in Antibiotic Development

Introduction

David L. Pruess, an accomplished inventor based in North Caldwell, NJ, has made significant contributions to the field of microbiology and antibiotic development. With a portfolio of seven patents, his innovative work has advanced the understanding and application of antibiotics, particularly through fermentation processes.

Latest Patents

Two of David's latest patents showcase his pioneering work. The first is for a novel bioactive substance, specifically 2-(3-Alanyl)clavam antibiotic, which is produced during the fermentation of *Streptomyces clavuligerus*. This substance exhibits notable antimicrobial activity in vitro and antifungal properties in natural environments. The second patent details Antibiotic 1745A/X, a new antibiotic generated by fermenting the microorganism *Streptomyces antibioticus* (ATCC 11891) using erythronolide A oxime as a substrate. Antibiotic 1745A/X serves as an effective antibacterial agent, reinforcing Pruess's dedication to combating bacterial infections.

Career Highlights

David L. Pruess currently contributes his expertise at Hoffmann-La Roche Inc., where he applies his knowledge in pharmaceutical development. His scientific acumen and innovative mindset have been instrumental in driving forward the research and development of new antibiotics, which are critical in addressing bacterial resistance issues.

Collaborations

Throughout his career, David has collaborated with talented professionals such as James Parnell Scannell and Richard W. Kierstead. These collaborations have enhanced the research environment, leading to the successful development of antibiotics and other bioactive substances, benefiting both the scientific community and public health.

Conclusion

David L. Pruess stands out as an influential inventor in the realm of antibiotic research. His contributions through innovative patents and collaborative efforts continue to pave the way for new solutions in medical treatments, reinforcing the importance of research and innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…